Gastric Cancer:
sirexatamab (DKN-01)
+ tislelizumab + chemotherapy 
Sirexatamab (DKN-01) in gastric cancer
Posters/manuscripts for the gastric cancer indication
- DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B
- DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
- DisTinGuish: Tislelizumab combination: ASCO 2023 poster
- DisTinGuish: Tislelizumab combination: SITC 2022 poster
- DisTinGuish: Tislelizumab combination: ESMO 2022 poster
- WaKING: Atezolizumab combination: ESMO 2022 poster
- DisTinGuish: ASCO GI 2022 poster
- DisTinGuish: Tislelizumab combination: ESMO 2021 poster
- P102 Keytruda Combination Manuscript: Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
- P102 Keytruda PD-1 Experienced Patients: SITC 2020
- P102 Keytruda Combination PD-1 Naïve Patients: ASCO GI 2020
- Paclitaxel combination: AACR 2018